Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole Versus Tamoxifen in Hormone-Responsive Postmenopausal Breast Cancer Patients
Phase 3
- Conditions
- hormone-responsive postmenopausal primary breast cancer
- Registration Number
- JPRN-C000000057
- Lead Sponsor
- -SAS BC 04 executive committee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
(1)invasive carcinoma of other organs (less than 5 years after the last treatment) (2)Past breast cancer (3)Past deep venous embolism (4)HRT(hormone replacement therapy) for symptoms of menopause within 4weeks before treatment (5)Metachronous or synchronous bilateral breast cancer (6)Patients judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method